Altimmune logo

Altimmune

ALT | NASDAQ
Chart Builder DCF Calculator
$1.56
-$0.08 (-5.17%)
At close: Nov 16, 2026, 4:00 PM ET
$1.57
+$0.01 (+0.64%)
After-hours: Nov 16, 2026, 7:57 PM ET
-5.17%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
37.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #602/1021 (Top 59%)

Key Statistics

Market Data

Market Cap $320.23M
1D Range
1.50 1.68
52W Range
1.50 6.18

Valuation (TTM)

PE -2.17
PB 0.72
EV/EBITDA -0.90

Valuation (NTM)

Forward PE N/A
Forward PEG 0.06
Price Target $10.00
Loading financial charts...

Profile

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, prev...

Sector Healthcare
Industry Biotechnology
Employees 57
IPO Date May 26, 2017
Fiscal Year January - December

Latest News

No news articles available yet.

Earnings

Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
4
Consensus
Buy
Price Target
$10.00
Upside
+541.03%
Buy (4)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.